Tiantian Li , Jie Zhang

Institute of Life Science, Jiyang College of Zhejiang A&F University, Zhuji, 311800, China
Author    Correspondence author
International Journal of Molecular Medical Science, 2024, Vol. 14, No. 4   
Received: 03 Jun., 2024    Accepted: 07 Jul., 2024    Published: 19 Jul., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The advent of genomic studies has significantly advanced our understanding of depression and its treatment, paving the way for personalized medicine. This review explores the integration of pharmacogenomics and other omic technologies in the treatment of depression, highlighting the potential for individualized care. Pharmacogenomic studies have identified several single nucleotide polymorphisms (SNPs) that influence the efficacy of antidepressants and mood stabilizers, although their clinical application remains limited. Genome-wide association studies have further elucidated genetic predictors of treatment-resistant depression, suggesting potential biomarkers for personalized treatment. Despite these advancements, the translation of genetic findings into clinical practice has been slow, with current diagnostic and treatment strategies still largely symptom-based. However, the use of pharmacogenomic testing has shown promise in improving treatment outcomes by guiding medication selection. Future research should focus on integrating multi-omic data to develop comprehensive predictive models for treatment response, ultimately enhancing the precision of depression management.

Hepatitis B virus (HBV); Vaccination; Epidemiology; Hepatocellular carcinoma (HCC); Global health strategies